News

GlobalData on MSN16h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
Devdiscourse1d
Mounjaro Overshadows Trulicity in Life-Saving Diabetes Battle
Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...
Medical Dialogues21h
Tirzepatide Matches dulaglutide in Heart Protection, Offers Added Benefits in SURPASS-CVOT trial
Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...
STAT1d
Pharmalittle: We’re reading about Prasad’s downfall at FDA, Moderna job cuts, and much more
Moderna announced layoffs affecting 10% of its workforce amid government and competitive challenges to its vaccine business ...
Indianapolis Business Journal1d
Lilly’s Mounjaro gets mixed results in extensive study vs. Trulicity
A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...
Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...